Sugi Predict

Sugi Predict / Compounds / SCHEMBL3250896

SCHEMBL3250896

SCHEMBL3250896

C[C@H](N)C(=O)Nc1cccc2ccccc12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 2/20 0.65
▸ KDM4E B2RXH2 4/20 0.64
▸ GAA P10253 3/20 0.64
▸ MAPT P10636 3/20 0.57
▸ POLB P06746 2/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ RAB9A P51151 4/20 0.55
▸ EPHX1 P07099 1/20 0.55
▸ ANPEP P15144 1/20 0.55
▸ NPC1 O15118 2/20 0.54
▸ CYP1A2 P05177 2/20 0.54
▸ CYP3A4 P08684 2/20 0.54
▸ CYP2C19 P33261 2/20 0.54
▸ CYP2D6 P10635 1/20 0.54
▸ CYP2C9 P11712 1/20 0.54
▸ XIAP P98170 1/20 0.53
▸ ALDH1A1 P00352 3/20 0.53
▸ GSK3B P49841 1/20 0.53
▸ HPGD P15428 1/20 0.53
▸ KMT2A Q03164 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19549091 1.00 IDO1 (0.65) IDO1KDM4EGAAMAPTPOLB
SCHEMBL7448781 0.90 KDM4E (0.55) IDO1KDM4EGAAMAPTPOLB
Hydrochloric Acid SCHEMBL8740055 0.88 KDM4E (0.54) IDO1KDM4EGAAMAPTPOLB
SCHEMBL27317144 0.87 KDM4E (0.60) IDO1KDM4EGAAMAPTPOLB
SCHEMBL12310942 0.87 KDM4E (0.60) IDO1KDM4EGAAMAPTPOLB
SCHEMBL27317142 0.87 KDM4E (0.60) IDO1KDM4EGAAMAPTPOLB
SCHEMBL171696 0.86 KDM4E (0.62) KDM4EGAAMAPTPOLBSMN1; SMN2
SCHEMBL18602340 0.83 KDM4E (0.59) KDM4EGAAMAPTPOLBSMN1; SMN2
SCHEMBL18952821 0.83 KDM4E (0.59) KDM4EGAAMAPTPOLBSMN1; SMN2
SCHEMBL9850400 0.83 KDM4E (0.59) KDM4EGAAMAPTPOLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9833768-B2 Affinity reagents for protein purification IMPOSSIBLE FOODS INC. (US) 2017-12-05 — — US claimed
US-20170320041-A1 AFFINITY REAGENTS FOR PROTEIN PURIFICATION IMPOSSIBLE FOODS INC. 2017-11-09 — — US claimed
US-9737875-B2 Affinity reagents for protein purification IMPOSSIBLE FOODS INC. (US) 2017-08-22 — — US claimed
US-20240083839-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-03-14 — — US disclosed
EP-4225730-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS The Regents of the University of California (US) 2023-08-16 — — EP disclosed
WO-2022076507-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-04-14 — — WO disclosed
CN-111410647-B Mu opium receptor bias agonist and medical application thereof 中国人民解放军军事科学院军事医学研究院 2021-08-17 — — CN disclosed
CN-111410647-A Mu opium receptor bias agonist and medical application thereof 中国人民解放军军事科学院军事医学研究院 2020-07-14 — — CN disclosed
EP-2206704-A1 Pharmaceutically active diazepanes Novartis AG (CH) 2010-07-14 — — EP disclosed
EP-1874739-B1 PHARMACEUTICALLY ACTIVE DIAZEPANES NOVARTIS AG (CH) 2010-05-26 — — EP disclosed
US-20080300237-A1 Pharmaceutically Active Diazepanes OBERHAUSER BERNDT 2008-12-04 — — US disclosed
EP-1874739-A1 PHARMACEUTICALLY ACTIVE DIAZEPANES Novartis AG (CH) 2008-01-09 — — EP disclosed
WO-2006111371-A1 PHARMACEUTICALLY ACTIVE DIAZEPANES NOVARTIS AG (CH) 2006-10-26 — — WO disclosed
US-20060148780-A1 Diazepanes derivatives useful as ifa inhibitors OBERHAUSER BERNDT 2006-07-06 — — US disclosed
EP-1590342-A1 DIAZEPANES DERIVATIVES USEFUL AS LFA INHIBITORS Novartis AG (CH) 2005-11-02 — — EP disclosed
WO-2004065382-A1 DIAZEPANES DERIVATIVES USEFUL AS LFA INHIBITORS NOVARTIS AG (CH) 2004-08-05 — — WO disclosed
WO-2003027315-A2 AMIDASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM DIVERSA CORPORATION (US) 2003-04-03 — — WO disclosed
US-5985632-A Peptide amidase from xanthomonas DEGUSSA AKTIENGESELLSCHAFT (DE) 1999-11-16 — — US disclosed
EP-0759066-A1 PROCESS FOR OBTAINING MICRO-ORGANISMS CONTAINING PEPTIDE AMIDASE, MICRO-ORGANISMS OBTAINED THEREWITH, PEPTIDE AMIDASES CONTAINED IN THEM AND USE THEREOF Degussa Aktiengesellschaft (DE) 1997-02-26 — — EP disclosed
WO-1995030740-A1 PROCESS FOR OBTAINING MICRO-ORGANISMS CONTAINING PEPTIDE AMIDASE, MICRO-ORGANISMS OBTAINED THEREWITH, PEPTIDE AMIDASES CONTAINED IN THEM AND USE THEREOF DEGUSSA AKTIENGESELLSCHAFT (DE) 1995-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300237-A1 Pharmaceutically Active Diazepanes VCAM1, ICAM1, CD69 IDO1 454/4885KDM4E 2996/4885GAA 2633/4885
US-20060148780-A1 Diazepanes derivatives useful as ifa inhibitors ICAM1, VCAM1, FLI1 IDO1 200/4885KDM4E 2753/4885GAA 2315/4885
US-20170320041-A1 AFFINITY REAGENTS FOR PROTEIN PURIFICATION RAB5IF, MRPL21, RPS27A IDO1 4251/4885KDM4E 3795/4885GAA 2676/4885
US-20240083839-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS PRMT8, SIRT1, PRMT3 IDO1 3142/4885KDM4E 855/4885GAA 595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.